SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is drawing significant attention as its community debates its immediate future, with some anticipating major "altseason" gains fueled by ongoing technical breakouts and rumors of potential new exchange listings. Proponents emphasize its core utility as fast, low-fee digital money and the transformative potential of upcoming protocol upgrades like LitVM. However, a strong contingent remains highly skeptical, labeling it a "dead coin" amid broader crypto market volatility.

Polygon

Polygon is experiencing a surge in conversation fueled by strong market momentum and its ongoing Open Money Stack Initiative, alongside reports of significant on-chain revenue growth and strategic token burning. The community is actively discussing Polygon's perceived undervaluation and its pivotal role as a scalable Layer 2 solution for Ethereum, anticipating its potential to dominate the payments sector amidst growing institutional interest and debates around its token's branding.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi ($FIS) is actively trending due to widespread community excitement, primarily driven by persistent rumors of new major exchange listings like Coinbase, coupled with noticeable increases in trading volume. The community is bullish, emphasizing its core utility as a liquid staking protocol with AI-integrated and cross-chain bridging technology, seeing it as an undervalued asset poised for significant "altseason" gains within the multi-chain crypto landscape.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending amidst strong community sentiment, driven by its innovative "Airlock" mechanism where over 35% of the token supply has been voluntarily locked. This community-driven supply control fosters a "Make Holding Great Again" narrative, aiming for broad exchange listings and is further buoyed by recent celebrity engagement. The highly bullish community actively champions AIRCOIN as a revolutionary and undervalued project within the crypto space.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

The biotech sector, reflected in LABU's performance, continues to capture market attention amid accelerating advancements in AI-driven drug discovery and expectations of accommodative monetary policy. The community is actively debating the sustainability of this strong upward trend, with many anticipating further sector growth and a rotation of capital into biotech innovation. Discussions highlight the transformative impact of artificial intelligence on pharmaceutical research and development, contrasting the sector's momentum against broader market concerns.

What is Mars Protocol?  Mars Protocol consists of a money market, called Red Bank, and a generalized credit primitive called Rover. Mars Protocol utilizes a so-called hub and outpost topology, whereby its base, Mars Hub acts as a command center for numerous outposts. Each outpost consists of an instance of Red Bank and Rover and the first of many outposts will be the Osmosis chain.

Mars

MARS CRYPTO is trending due to community excitement surrounding a nascent meme token, with users speculating on its potential for rapid growth and drawing parallels to other popular meme coins. While some discussion also involves an upcoming space technology ETF sharing the $MARS ticker, the current speculative interest largely centers on the cryptocurrency.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic (LUNC) is drawing significant community attention, catalyzed by surging trading volume and substantial token burns from major exchanges. Discussions are vibrant around potential new exchange listings and ongoing ecosystem developments like LUNCVERSE, leading many to view LUNC as an undervalued asset poised for a major resurgence within the evolving altcoin landscape.

Constellation Software Inc

Constellation Software is trending as investors assess its robust Q3 results, which reported strong revenue and free cash flow growth amidst a significant share price pullback. The community is actively debating whether this represents a rare buying opportunity due to perceived undervaluation and solid fundamentals, while also considering potential impacts from AI on its niche software empire. Analysts largely maintain bullish outlooks, highlighting the company's proven acquisition strategy and stable leadership.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending amid intense community debate as its underlying biotech index (XBI) continues a robust and sustained rally, defying expectations for a significant pullback. Many investors express frustration over XBI's persistent upward momentum, viewing it as an overextended 'pump' or a 'hideout' for market makers, while others anticipate further gains driven by sector rotation and buyout activity, creating a highly polarized outlook for this bear-leveraged ETF.

Willow Lane Acquisition Corp. is a blank check company, which engages for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 3, 2024 and is headquartered in New York, NY.

Willow Lane Acquisition Corp. - Ordinary Shares - Class A

Willow Lane Acquisition Corp. is trending as the community anticipates its merger with Boost Run, an AI infrastructure company widely considered an undervalued "sleeping giant" in a high-demand sector. Investors are actively discussing the imminent S-4 filing as the next catalyst, drawing comparisons to successful AI infrastructure plays and expecting a significant run in the burgeoning data center market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>JNJ agreed to drug discounts and tariff exemptions under a White House deal.</li><li>The agreement builds on its existing $55 billion U.S. manufacturing and R&amp;D plan.</li><li>New facilities add to projects already underway in North Carolina and Pennsylvania.</li></ul><p>Johnson &amp; Johnson (JNJ) said on Thursday it has reached a voluntary agreement with the U.S. government to expand access to medicines, lower drug costs for American patients, and secure exemptions from U.S. tariffs on its pharmaceutical products, while advancing its domestic manufacturing plans.</p><h2 class="st-heading-2"><strong>Drug Pricing And Tariff Exemptions</strong></h2><p>As part of the deal, JNJ will allow Americans to buy medicines at significantly discounted rates through TrumpRx.gov, a government-backed direct-to-patient platform. The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.</p><p>The deal grants JNJ’s pharmaceutical products exemptions from U.S. tariffs and aligns with the administration’s “most-favored-nation” pricing framework.</p><p>“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” CEO Joaquin Duato said in a statement.&nbsp;</p><h2 class="st-heading-2"><strong>US Manufacturing Commitments</strong></h2><p>JNJ said the agreement builds on its previously announced $55 billion U.S. investment plan through early 2029, which focuses on expanding domestic manufacturing, research and development, and technology.&nbsp;</p><p>As part of the plan, the company announced two additional U.S. manufacturing facilities, including a cell therapy site in Pennsylvania and a drug product manufacturing facility in North Carolina. Construction is already underway at the company’s $2 billion biologics facility in Wilson, North Carolina, a project expected to support around 5,000 manufacturing and construction jobs.&nbsp;</p><p>Separately, JNJ has committed $2 billion over the next 10 years to a biopharmaceutical site in Holly Springs, North Carolina, which is expected to create about 120 jobs. The company said it expects to announce further U.S. investments later this year.</p><h2 class="st-heading-2"><strong>White House Drug Deals Expand</strong></h2><p>The announcement follows&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-strikes-new-drug-price-deals-with-roche-novartis-merck-and-other-pharma-giants/cLe0duBREtP">similar agreements struck last month</a> between the White House and other major drugmakers, including Amgen, Bristol Myers Squibb, Pfizer, Gilead Sciences, GSK, Merck, Novartis, Roche and Sanofi.</p><p>The deals require steep discounts through TrumpRx, most-favored-nation pricing for Medicaid, expanded U.S. manufacturing, and restrictions on stockpiling drugs to avoid tariffs.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment was ‘bearish’ amid ‘high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/jnj_ss_png_1d85f7828a.webp" alt="jnj ss.png" width="967" height="142"><figcaption>JNJ sentiment and message volume as of January 8| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/JNJ">JNJ’s stock</a> has risen 49% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs 

The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.

Equity

Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

In the closing of the recent trading day, Amgen (AMGN) stood at $330.05, denoting a -3.39% move from the preceding trading day.

Amgen (NASDAQ:AMGN) Price Target Raised to $319.00 at Truist Financial

Truist Financial increased their target price on Amgen from $318.00 to $319.00 and gave the company a "hold" rating in a research note on Thursday...

RVMD Stock Hits a Record High on Rumored Takeover Interest

Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.

J&J's Innovative Medicine Segment in Q4: Here's What to Watch

JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.

ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline

AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.

Robeco Institutional Asset Management B.V. Has $123.48 Million Stock Position in Amgen Inc. $AMGN

Robeco Institutional Asset Management B.V. lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.5% during the third quarter, according to the company in its most recent Form...

CX Institutional Increases Stake in Amgen Inc. $AMGN

CX Institutional increased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and...

Cerity Partners LLC Sells 6,837 Shares of Amgen Inc. $AMGN

Cerity Partners LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange...

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

AMGN
AMGEN Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AMGN News

AMGNAMGEN Inc.